SPL 2.11% 9.3¢ starpharma holdings limited

At 550mil AUD, Viralytic is dirt cheap acquisition for Merck....

  1. 390 Posts.
    lightbulb Created with Sketch. 133
    At 550mil AUD, Viralytic is dirt cheap acquisition for Merck.
    They probably can't afford to bid on SPL anytime soon, SPL's vivagel (including recurrent treatment) alone will worth north of $1.52. Any offer will have to be in excess of 1B to get any dendrimer tech transfer, don't forget that once a bid is made public by 1 big pharma, more bidder will emerge. 170% north of today's price is far from compelling.
    SPL business model and line up resemble like an early stage CSL, which now as we know has a 71B MC.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.